Julia Douglas Clinical Oncology Society of Australia Annual Scientific Meeting 2022

Abstracts this author is presenting:

• Pembrolizumab+Chemotherapy vs Placebo+Chemotherapy by PD-L1 combined positive score 1-9, 10-19, and ≥20 for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer: KEYNOTE-355 subgroup analysis — Poster session 1